Idaho recently joined 47 other states and the federal government in a settlement against Qualitest Pharmaceuticals due to their mislabeled Qualitest-branded multivitamin, according to Attorney General Lawrence Wasden.

Qualitest, a manufacturer of generic pharmaceutical products owned by Endo Pharmaceuticals, profited from misinformation. Through labeling and promotion, they indicated that their vitamins contained the level of fluoride recommended by the U.S. Food and Drug Administration (FDA) and the American Dental Association (ADA). In reality, it had half that amount.

Dr. Stephan Porter, a dentist in Florida, originally blew the whistle, sharing the news about Qualitest tablets to light after learning about the actual levels of fluoride used, according to New York Attorney General Eric Schneiderman.

Qualitest will pay $87,467 to Idaho, resolving the allegation of unlawful labeling practices. Overall, Qualitest is set to pay $39,000,000 to the 48 states and federal governments, plus taxes. The National Association of Medicaid Fraud Control Units worked alongside the federal government to investigate and plan settlement negotiations.

Additionally, more than 100 women filed a suit against the aforementioned pharmaceutical company because they allegedly mispackaging birth control pill, resulting in unwanted pregnancies.

On February 1st, a new initiative honoring the Qualitest name was announced by parent company Endo. The Qualitest Scholarship Program was designed to be awarded to students pursuing higher education in the Huntsville, Alabama region.